Worth reading
58In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
271
Millions of yen (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending February 20274 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,192 million+22.6%
Operating profit¥199 million
Operating profit margin9.1 %
Results for the three months of the current quarter
Net Sales
¥2,192 million
Operating profit
¥199 million
Full-year earnings forecast
Net Sales
¥9,828 million
Operating profit
¥933 million
R&D expenses
¥1,042 million
EBITDA
¥1,681 million
Operating profit margin
9.5 %
EBITDA margin
17.1 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Operating profit was broadly in line with the forecastNew initiatives
- Development and commencement of shipments of a 436 nm laser for quantum communications
- Delivery of the first quantum communications laser unit to LQUOM
- Provision of a research and development environment and prototyping equipment to SCALE photonics
- Joint development of new optical devices with SCALE photonics
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥364 millionYear-on-year change in amount210
- EBITDA margin16.6 %Year-on-year change (points)8
Segment results
- SemiconductorsNet Sales¥1,576 millionYear-on-year change in amount¥741 million
- HealthcareNet Sales¥326 millionYear-on-year change in amount¥-20 million
- New domainNet Sales¥289 millionYear-on-year change in amount¥-317 million
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending February 2027 |
| Net Sales | ¥2,192 million (YoY +22.6%) |
| Operating profit | ¥199 million |
| Operating profit margin | 9.1 % |
| Results for the three months of the current quarter | Net Sales ¥2,192 million / Operating profit ¥199 million |
| Full-year earnings forecast | Net Sales ¥9,828 million / Operating profit ¥933 million / R&D expenses ¥1,042 million / EBITDA ¥1,681 million / Operating profit margin 9.5 % / EBITDA margin 17.1 % |
| Self-assessment against the plan | Operating profit was broadly in line with the forecast |
| Segment results | Segment Semiconductors / Net Sales ¥1,576 million / Year-on-year change in amount ¥741 million, Segment Healthcare / Net Sales ¥326 million / Year-on-year change in amount ¥-20 million, Segment New domain / Net Sales ¥289 million / Year-on-year change in amount ¥-317 million |
| Key KPIs | Indicator name EBITDA / Value ¥364 million / Year-on-year change in amount ¥210 million, Indicator name EBITDA margin / Value 16.6 % / Year-on-year change (points) 8 % |
| New initiatives | Development and commencement of shipments of a 436 nm laser for quantum communications, Delivery of the first quantum communications laser unit to LQUOM, Provision of a research and development environment and prototyping equipment to SCALE photonics, Joint development of new optical devices with SCALE photonics |
Items this document does not state (20)
Ordinary incomeNet incomeGross Profit MarginSelling, general and administrative expensesProgress against full-year forecastBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue in the semiconductor business remained solid against the backdrop of a strong semiconductor market. In the healthcare business, some shipments were shifted to the second quarter or later, while in the new business, delays in the arrival of certain materials for data center products shifted the scheduled revenue to the second quarter. In addition, in light of changes in the procurement environment and rising raw material prices, the healthcare business is discussing transaction terms with customers.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.